Inotuzumab ozogamicin
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD22 |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 635715-01-4  |
| ATC code | None |
| UNII | P93RUU11P7 |
| KEGG | D08933  |
| Chemical data | |
| Formula | C6518H10002N1738O2036S42 |
| Mol. mass | 150,000 Daltons |
 (what is this?) (verify) |
|
Inotuzumab ozogamicin (CMC-544) is a humanized monoclonal antibody for the treatment of cancers.[1] The monoclonal antibody (for CD22) is linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).[2]
This drug was developed by Wyeth.
It is undergoing numerous clinical trials,[3] including two phase II trials for Non-Hodgkin lymphoma. A phase III trial has been terminated.
[edit] See also
[edit] References
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Inotuzumab ozogamicin, American Medical Association.
- ^ Takeshita, A; Shinjo, K; Yamakage, N; Ono, T; Hirano, I; Matsui, H; Shigeno, K; Nakamura, S et al (2009). "CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.". British journal of haematology 146 (1): 34–43. doi:10.1111/j.1365-2141.2009.07701.x. PMID 19388933.
- ^ http://clinicaltrials.gov/ct2/results?term=Inotuzumab+ozogamicin
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
